News
Completion of Phase 2a Clinical Trial of GT-02037 Conducted at Okayama University Hospital
We are pleased to announce that the investigator-led clinical trial titled “Early Phase II, Randomized, Open-Label, Crossover, Single-Dose Study to evaluate the effect of GT-02037 subcutaneous formulation on blood levels of Growth Hormone and its Safety compared to Octreotide subcutaneous formulation in Japanese patients with Acromegaly” conducted at Okayama University Hospital has now achieved its enrollment target and the final report has been completed. The results of this clinical trial will be presented by Okayama University Hospital at academic conferences and other venues in the near future.
Clinical trial details: Japan Registry of Clinical Trials
Last updated: